Keeping Track: A Burst Of Breakthroughs, A Priority Review For Keytruda, And Some Supplemental Submissions
Executive Summary
The latest drug development news and highlights from our US FDA Performance Tracker.
You may also be interested in...
Keeping Track: Nektar Withdraws Oxycodegol NDA As Novel Submission Pileup Continues
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: Recarbrio Approval Highlights Two-Week Roundup
The latest drug development news and highlights for our US FDA Performance Tracker.
Keeping Track: NME Approvals For Evenity And Balversa; Non-NME Approvals For Dovato And Keytruda; But An RTF For Fintepla
The latest drug development news and highlights from our US FDA Performance Tracker.